Aarkstore Enterprise

Aarkstore Market Research Report - Frontier

Pharma: Prostate Cancer - Identifying and
Commercializing First-in-Class Innovation
Browse Full Report @
http://www.aarkstore.com/pharmaceuticals-healthcare/87810/frontier-pharmaprostate-cancer-identifying-and-commercializing-first-in-class-innovation

Published: Nov 2014 | 91 Pages

Discounted Market Research Reports available on Aarkstore.com Offer valid till 28th
February, 2015
For more inquiries, contact at +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com

Summary

Aarkstore Enterprise
Exceptionally Large and Innovative Pipeline
The prostate cancer pipeline is among the largest in the pharmaceutical industry with
484 products in active development across all stages. The range of mechanisms of
action employed by these compounds is also highly diverse, especially in comparison to
the existing market landscape. More pertinently, the degree and proportion of
breakthrough innovations in this pipeline is exceptional; GBI Research analysis
identified 174 first-in-class programs in the prostate cancer pipeline, acting on 122
first-in-class molecular targets. This accounts for some 36% of all products with a
disclosed molecular target and is reflective of the high degree of innovation in this
indication. This has far-reaching strategic implications for all market participants, as,
despite the high attrition rate in prostate cancer, it is highly likely many of the first-inclass technologies will reach the market over the coming decade and may transform the
clinical and commercial landscape.
Alignment of First-in-Class Molecular Target with Disease Causation
One of the key trends in oncology and in prostate cancer in particular over the last
decade is the clinical and commercial impact of targeted therapies designed to target
proteins in signaling pathways that are strongly associated with disease progression. By
aligning the molecular targets for therapeutic intervention with disease causation
and/or propagation, these therapies limit the systemic cytotoxic effects whilst
inhibiting tumor-promoting signaling pathways. Such strategies thereby typically
achieve superior efficacy and safety profiles.
Our proprietary analyses demonstrate significant levels of differentiation as to how
well the first-in-class products and their respective molecular targets align to
underlying gene and protein level mutations and dysfunction. More advanced analytics
further substantiated these findings as strong levels of differentiation in the scientific
and clinical rationale for first-in-class molecular targets emerged. Furthermore, clear
frontrunners were identified by integrating analyses to assess the accessibility of
molecular targets for therapeutic compounds, the size of the target patient population
that would benefit from therapeutic intervention, and the expected positioning of the
first-in-class products based on the molecular targets and mechanisms of action of

Aarkstore Enterprise
currently marketed products.
These insights and a detailed review of the available evidence from scientific studies
substantiate the perspective that first-in-class-product technology in its own right is
not sufficient to offer a compelling scientific and clinical rationale. However, a range of
products offer very significant scientific and clinical promise and could therefore result
in a strong commercial proposition with the prospect of clinically and commercially
transformative products in the future.
A Deals Landscape with Numerous Investment Opportunities
Analysis has confirmed that 169 of the 174 first-in-class products have not been
involved in a licensing or co-development deal. Although many act on targets that are
not yet strongly substantiated in terms of their therapeutic potential in prostate cancer
in clinical studies, there are many which are supported by promising in vivo and in
vitro preclinical evidence, and as such are highly promising prostate cancer therapies.
Indeed, breakthrough innovations are highly desirable as an investment option.
However, most deals involving first-in-class products were either preclinical or Phase I
development, whereas advance-in-class and addition-to-class product deals were
typically made in Phases II and III, therefore showing significant differentiation. These
findings have significant strategic implications for both biotech companies seeking to
out-license products and firms with an interest in in-licensing first-in-class products
with strong clinical and commercial prospects.
Scope
The report analyzes innovation in prostate cancer, in the context of the overall pipeline
and current market landscape. In addition, it analyzed the deals landscape surrounding
first-in-class products in prostate cancer, and pinpoints opportunities for in-licensing.
The report covers and includes - A brief introduction to prostate cancer, including symptoms, pathophysiology, and
overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between market and pipeline and particular

Aarkstore Enterprise
focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the
basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets with a particular
focus on early-stage programs of which clinical utility has yet to be evaluated, as well as
literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for prostate cancer
therapies and benchmarking of deals involving first-in-class versus non-first-in-classproducts.
Reasons to buy
The report will assist business development and enable marketing executives to
strategize their product launches, by allowing them to - Understanding of the focal shifts in molecular targets in the prostate cancer pipeline.
- Understanding of the distribution of pipeline programs by phase of development,
molecule type and molecular target.
- Access a scientific and clinical analysis of first-in-class developmental programs for
prostate cancer, benchmarked against non-first-in-class targets.
- Access a list of the first-in-class therapies potentially open to deal-making
opportunities
Browse complete Report on:
http://www.aarkstore.com/pharmaceuticals-healthcare/87810/frontierpharma-prostate-cancer-identifying-and-commercializing-first-in-classinnovation

Table of Contents:

Aarkstore Enterprise
2 Executive Summary 4
2.1 Active Pipeline Reflects Large Market with Significant Unmet Needs 4
2.2 Market Landscape to Grow in Diversity over Coming Decade 4
2.3 Deals Landscape Presents Significant Investment Opportunities for First-in-Class
Products 4
3 The Case for Innovation in Prostate Cancer 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product
Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.1.1 Epidemiology 10
4.1.2 Etiology 11
4.1.3 Disease Pathophysiology 12
4.1.4 Disease Symptoms 14
4.1.5 Disease Staging and Diagnosis 14
4.1.6 Treatment 16
4.2 Overview of Marketed Products 19
4.2.1 Hormonal Therapies 19
4.2.2 Chemotherapy 20
4.2.3 Therapeutic Vaccines 20
4.2.4 Targeted Therapies (Second Generation Anti-androgens) 21
4.2.5 Bone Metastasis Treatments 21
5 Assessment of Pipeline Product Innovation 22
5.1 Prostate Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 22
5.2 Comparative Distribution of Programs between the Prostate Cancer Market and
Pipeline by Molecular Target 28
5.3 First-in-Class Pipeline Programs Targeting Novel Molecule Targets 28
6 Signaling Network, Disease Causation and Innovation Alignment 35
6.1 The Complexity of Signaling Networks in Oncology 35

Aarkstore Enterprise
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular
Target Integration 36
6.3 First-in-class Target Matrix Assessment 38
7 First-in-Class Target and Pipeline Program Evaluation 42
7.1 Pipeline Programs Targeting Human Double Minute 2 42
7.1.1 Overview of Pipeline Programs Targeting MDM2 44
7.2 Pipeline Programs Targeting AKT1 44
7.2.1 Overview of Pipeline Programs Targeting AKT1 46
7.3 Pipeline Programs Targeting Tumor Protein p53 46
7.3.1 Overview of Pipeline Programs Targeting p53 47
7.4 Pipeline Programs Targeting Mitogen-Activated Protein Kinase 47
7.4.1 Overview of Pipeline Programs Targeting MAPK 49
7.5 Pipeline Programs Targeting Specificity Protein 1 49
7.5.1 Overview of Pipeline Programs Targeting Specificity Protein 1 52
7.6 Pipeline Programs Targeting X-linked Inhibitor of Apoptosis Protein 52
7.6.1 Overview of Pipeline Programs Targeting X-linked Inhibitor of Apoptosis Protein
53
7.7 Pipeline Programs Targeting Hypoxia-Inducible Factor 1 53
7.7.1 Overview of Pipeline Programs Targeting Hypoxia-Inducible Factor 1 55
7.8 Pipeline Programs Targeting Galectin-3 55
7.8.1 Overview of Pipeline Programs Targeting Galectin-3 56
7.9 Pipeline Programs Targeting Prostate Specific Membrane Antigen 57
7.9.1 Overview of Pipeline Programs Targeting Prostate Specific Membrane Antigen 59
7.10 Pipeline Programs Targeting Aurora Kinase 59
7.10.1 Overview of Pipeline Programs Targeting Aurora Kinase 61
7.11 Conclusion 62
8 Deals and Strategic Consolidations 63
8.1 Industry-wide First-in-Class Deals 63
8.2 Licensing Deals 65
8.3 Co-developments 68
8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals 70
9 Appendix 75
9.1 References 75
9.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular

Aarkstore Enterprise
Target Integration Tables 82
9.3 Abbreviations 89
9.4 Expert Panel Validation 90
9.5 Contact Us 91
9.6 Disclaimer
List Of Tables
Table 1: Prostate Cancer Risk Factors 12
Table 2: Prostate Cancer, Disease Stage Classification
List Of Figures
Figure 1: Innovation Trends in Product Approvals 6
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Product Post
Marketing Approval 8
Figure 3: Percentage of Men Diagnosed with Prostate Cancer in the US by Age (%),
20052009 10
Figure 4: Average Number of New Cases and Age-Specific Incidence Rates per
100,000 Population in the UK, 20082010 11
Figure 5: Prostate Cancer Treatment Algorithm (Stages I and II) 16
Figure 6: Prostate Cancer Treatment Algorithm (Stages III) 17
Figure 7: Prostate Cancer Treatment Algorithm (Stages IV) 18
Figure 8: Global Pipeline Overview 23
Figure 9: Molecular Target Classes of Pipeline Products 24
Figure 10 : Prostate Cancer, Molecular Targets 25
Figure 11: Molecular Target Category Comparison, Pipeline and Marketed Products 28
Figure 12: First-in-Class and Non-First-in-Class Pipeline Product Comparison 29
Figure 13: Prostate Cancer, First-in-Class Products in the Prostate Cancer Pipeline,
Part 1 30
Figure 14: Prostate Cancer, First-in-Class Products in the Prostate Cancer Pipeline,
Part 2 31
Figure 15: Prostate Cancer, First-in-Class Products in the Prostate Cancer Pipeline,
Part 3 32

Aarkstore Enterprise
Figure 16: Prostate Cancer, First-in-Class Products in the Prostate Cancer Pipeline,
Part 4 33
Figure 17: Signaling Networks of Functional Families in Prostate Cancer 37
Figure 18: First-in-Class Molecular Target Analysis Matrix (Part 1) 39
Figure 19: First-in-Class Molecular Target Analysis Matrix (Part 2) 40
Figure 20: First-in-Class Molecular Target Analysis Matrix (Part 3) 41
Figure 21: MDM2 as a Therapeutic Target 43
Figure 22: Pipeline Programs Targeting MDM2 44
Figure 23: AKT as a Therapeutic Target 45
Figure 24: Pipeline Programs Targeting AKT1 46
Figure 25: TP53 as a Therapeutic Target 47
Figure 26: Pipeline Programs Targeting p53 47
Figure 27: MAPK8 as a Therapeutic Target 49
Figure 28: Pipeline Programs Targeting MAPK 49
Figure 29: Sp1 as a Therapeutic Target 51
Figure 30: Pipeline Programs Targeting Specificity Protein 1 52
Figure 31: XIAP as a Therapeutic Target 53
Figure 32: Pipeline Programs Targeting X-linked Inhibitor or Apoptosis Protein 53
Figure 33: HIF1A as a Therapeutic Target 55
Figure 34: Pipeline Programs Targeting Hypoxia-Inducible Factor 1 55
Figure 35: Galectin3 as a Therapeutic Target 56
Figure 36: Pipeline Programs Targeting Galectin-3 56
Figure 37: PSMA as a Therapeutic Target 58
Figure 38: Pipeline Programs Targeting PSMA 59
Figure 39: Aurora Kinase as a Therapeutic Target 61
Figure 40: Pipeline Programs Targeting Aurora Kinase 61
Figure 41: Industry-wide Deals by Stage of Development, 20062014 63
Figure 42: Industry-wide Deals by Stage of Development, 20062014 64
Figure 43: Licensing Deals by Region, 20062014 65
Figure 44: Licensing Deals, 20062014 66
Figure 45: First-in-Class and Non-First-in-Class Comparison, 20062014 67
Figure 46: Market for Prostate Cancer, Global, Licensing Deals by Mechanism of
Action, 20062014 67
Figure 47: Co-development Deals by Region, 20062014 68

Aarkstore Enterprise
Figure 48: Co-development Deals, 20062014 69
Figure 49: Co-developments by Mechanism of Action, 20062014 69
Figure 50: First-in-class Programs with no Recorded Prior Deal Involvement, 2006
2014 (Part 1) 71
Figure 51: First-in-class Programs with no Recorded Prior Deal Involvement, 2006
2014 (Part 2) 72
Figure 52: First-in-class Programs with no Recorded Prior Deal Involvement, 2006
2014 (Part 3) 73
Figure 53: Signaling Networks of Functional Families in Prostate Cancer, Table 1 82
Figure 54: Signaling Networks of Functional Families in Prostate Cancer, Table 2 83
Figure 55: Signaling Networks of Functional Families in Prostate Cancer, Table 3 84
Figure 56: Signaling Networks of Functional Families in Prostate Cancer, Table 4 85
Figure 57: Signaling Networks of Functional Families in Prostate Cancer, Table 5 86
Figure 58: Signaling Networks of Functional Families in Prostate Cancer, Table 6 87
Figure 59: Signaling Networks of Functional Families in Prostate Cancer, Table 7 88
Figure 60: Signaling Networks of Functional Families in Prostate Cancer, Table 8 89
Related Market Research reports:
Generic Drugs Market in Japan 2015-2019
Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape,
2015
Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Lupus Erythematosus-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
Metastatic Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2015
Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent)
Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape,
2015
Meningitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
Pharmaceuticals & Healthcare Market Research Reports

Aarkstore Enterprise

About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions
worldwide. We specialize in providing online market business information on market research
reports, books, magazines, conference at competitive prices, and strive to provide excellent and
innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom